CC趋化因子受体9在小鼠和人非酒精性脂肪性肝炎进展中的作用
本研究探讨CCR9/CCL25轴在非酒精性脂肪性肝炎(NASH)中的作用。NASH患者血清CCL25及肝脏CCR9、CCL25表达较健康志愿者升高;Ccr9-/-小鼠在高脂高胆固醇饮食24周后,血清学和组织学均受保护免于NASH进展;CCR9拮抗剂可抑制小鼠NASH纤维化进展并减弱NAFLD相关肝细胞癌发生。
要点
- NASH患者血清CCL25及肝脏CCR9、CCL25表达较健康志愿者升高
- Ccr9-/-小鼠在高脂高胆固醇饮食24周后免于NASH进展
- CCR9拮抗剂可抑制小鼠NASH纤维化进展并减弱NAFLD相关肝细胞癌发生
核心结论
- CCR9/CCL25轴参与小鼠NASH模型中巨噬细胞募集和纤维化形成,为NASH治疗策略提供新见解。
- CCR9拮抗剂治疗可改善脂肪性肝炎进展,有望用于NASH患者治疗。
研究设计与样本
- 研究纳入经活检证实的非酒精性脂肪性肝病(NAFLD)患者,检测其血清和肝脏趋化因子表达。
- 野生型(WT)和Ccr9-/-小鼠接受高脂高胆固醇(HFHC)饮食24周以建立NASH模型。
- 体外评估CCR9缺陷肝星状细胞(HSC)的纤维化潜能。
- 在NASH小鼠中给予CCR9拮抗剂,观察纤维化进展。
- 在高脂饮食喂养并注射二乙基亚硝胺的小鼠中评估CCR9阻断对NAFLD相关肝细胞癌发生的影响。
主要发现
- NASH患者血清CCL25及肝脏CCR9和CCL25表达水平较健康志愿者升高。
- Ccr9-/-小鼠在高脂高胆固醇饮食诱导的NASH进展中,血清学和组织学均受到保护。
- 流式细胞术和免疫组化显示,高脂高胆固醇饮食喂养小鼠炎症肝脏中CCR9+CD11b+炎性巨噬细胞积聚,而Ccr9-/-小鼠中该细胞数量减少。
- 与人类NASH肝脏一致,NASH小鼠肝星状细胞表达CCR9,而CCR9缺陷肝星状细胞体外纤维化潜能降低。
- 给予CCR9拮抗剂可阻碍NASH小鼠纤维化进一步进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The number of patients with non-alcoholic steatohepatitis (NASH) is increasing globally. Recently, specific chemokine receptors have garnered interest as therapeutic targets in NASH. This is the first report to examine the role of the C-C chemokine receptor 9 (CCR9)/C-C chemokine receptor ligand 25 (CCL25) axis, and to reveal its therapeutic potential in NASH. METHODS: Patients with biopsy-proven non-alcoholic liver disease (NAFLD) were recruited and their serum and hepatic chemokine expression was examined. Furthermore, wild-type (WT) and Ccr9-/- mice were fed a high-fat high-cholesterol (HFHC) diet for 24 weeks to establish NASH. RESULTS: Serum CCL25, and hepatic CCR9 and CCL25 expression levels were increased in patients with NASH compared to healthy volunteers. Furthermore, Ccr9-/- mice were protected from HFHC diet-induced NASH progression both serologically and histologically. Flow cytometry and immunohistochemistry analysis showed that CCR9+CD11b+ inflammatory macrophages accumulated in the inflamed livers of HFHC diet-fed mice, while the number was reduced in Ccr9-/- mice. Consistent with human NASH livers, CCR9 was also expressed on hepatic stellate cells (HSCs) in mice with NASH, while CCR9-deficient HSCs showed less fibrogenic potential in vitro. Administration of a CCR9 antagonist hampered further fibrosis progression in mice with NASH, supporting its potential clinical application. Finally, we showed that CCR9 blockade attenuated the development of NAFLD-related hepatocellular carcinoma in HF diet-fed mice injected with diethylnitrosamine. CONCLUSIONS: These results highlight the role of the CCR9/CCL25 axis on macrophage recruitment and fibrosis formation in a murine NASH model, providing new insights into therapeutic strategies for NASH. LAY SUMMARY: Herein, we show that a specific chemokine axis involving a receptor (CCR9) and its ligand (CCL25) contributes to the progression of non-alcoholic steatohepatitis and carcinogenesis in humans and mice. Furthermore, treatment with a CCR9 antagonist ameliorates the development of steatohepatitis and holds promise for the treatment of patients with non-alcoholic steatohepatitis.
引用
- Morikawa R, Nakamoto N, Amiya T, et al. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol. 2020. PMID: 33038434. doi:10.1016/j.jhep.2020.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。